WaferGen BioSystems Announces Highly Successful Initial Customer Testing of Previously Unannounced Novel Target Enrichment Technology for Next-Gen Sequencing (NGS)
WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the successful completion of a proof-of-concept study using its newly-developed proprietary nano-qPCR technology for sample preparation prior to targeted re-sequencing on Next-Gen platforms.
View full press release